MDP:CC News and Press, Medexus Pharmaceuticals Inc.

FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and...

Lomiko Metals Inc. (LMR:CA) is expected to report for Q3 2024 Organto Foods Inc. (OGO:CA) is expected to report for Q1 2024 PreveCeutical Medical Inc. (PREV:CNX) is expected to report for Q1 2024 Blue Horizon Global Capital Corp Com (BHCC:CNX) is expected to report for Q1 2024 Per...

Evertz Technologies Limited (ET:CA) is expected to report $0.22 for Q4 2024 Transat A.T. Inc. Voting and Variable Voting Shares (TRZ:CA) is expected to report $-0.66 for Q2 2024 Medexus Pharmaceuticals Inc. (MDP:CA) is expected to report $-0.03 for Q4 2024 FP Newspapers Inc. (FP:CA) i...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended Mar...

Canadian Investment Regulatory Organization Trading Halt - MDP Canada NewsWire TORONTO , June 6, 2024 /CNW/ - The following issues have been halted by CIRO: Company: Medexus Pharmaceuticals Inc. TSX Symbol: MDP All Issues: Yes Reason: Pending News ...

Canadian Investment Regulatory Organization Trade Resumption - MDP Canada NewsWire TORONTO , June 6, 2024 /CNW/ - Trading resumes in: Company: Medexus Pharmaceuticals Inc. TSX Symbol: MDP All Issues: Yes Resumption (ET): 11:00 AM CIRO can make...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for rev...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) and medac, licensor of Medexus's c...

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024. Event : ...

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age group Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 26, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) to...